For the quarter ending 2026-03-31, AIM has $8,585K in assets. $6,460K in debts. $5,816K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Cash and cash equivalents | 5,816 | 2,347 | 476 | |
| Marketable investments | 63 | 62 | 359 | |
| Prepaid expenses and other current assets | 335 | 166 | 190 | |
| Total current assets | 6,214 | 2,575 | 1,025 | |
| Property and equipment, net | 62 | 80 | 89 | |
| Right of use asset, net | 320 | 436 | 496 | |
| Patent and trademark rights, net | 1,662 | 2,041 | 2,168 | |
| Other assets | 327 | 362 | 351 | |
| Total assets | 8,585 | 5,494 | 4,129 | |
| Accounts payable | 1,215 | 1,252 | 7,297 | |
| Accrued expenses | 671 | 679 | 573 | |
| Current portion of operating lease liability | 255 | 232 | 233 | |
| Current portion of note payable, net | 4,004 | 1,880 | 2,290 | |
| Total current liabilities | 6,145 | 4,043 | 10,393 | |
| Operating lease liability | 105 | 226 | 282 | |
| Preferred stock, value-Series BConvertible Preferred Stock | - | - | 0 | |
| Warrant liability | - | 7,302 | - | |
| Long-term note payable | 210 | - | - | |
| Preferred stock, value-Series AJunior Participating Preferred Stock | - | - | 0 | |
| Total liabilities | 6,460 | 11,571 | 10,675 | |
| Common stock, 0.001 par value, authorized shares - 350,000,000 issued and outstanding shares 8,223,782 and 3,069,875 as of march 31, 2026 and december 31, 2025, respectively | 8 | 3 | 1 | |
| Additional paid-in capital | 445,926 | 430,531 | 426,780 | |
| Accumulated deficit | -443,809 | -436,611 | -433,327 | |
| Total stockholders equity (deficit) | 2,125 | -6,077 | -6,546 | |
| Total liabilities and stockholders equity (deficit) | 8,585 | 5,494 | 4,129 | |
AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Inc. (AIM)